collection
MENU ▼
Read by QxMD icon Read
search

cardiology

shared collection
13 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27780804/how-i-treat-anticoagulation-in-atrial-fibrillation
#1
Benjamin A Steinberg
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and conveys a significant risk of morbidity and mortality due to related stroke and systemic embolism. Oral anticoagulation (OAC) is the mainstay of thromboembolism prevention and management of anticoagulation can be challenging. For patients without significant valvular disease, decisions around anticoagulation therapy are first based on the presence of additional stroke risk factors, as measured by the CHA2DS2-VASc score. Patients with increased CHA2DS2-VASc scores (by regional guidelines) should next be evaluated to determine if they are candidates for non-vitamin K antagonist oral anticoagulant (NOAC) therapy...
October 25, 2016: Blood
https://www.readbyqxmd.com/read/27637131/atrial-fibrillation
#2
(no author information available yet)
No abstract text is available yet for this article.
September 15, 2016: American Family Physician
https://www.readbyqxmd.com/read/27567408/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts-the-task-force-for-the-management-of-atrial-fibrillation-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the-european-heart
#3
Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, Anders Ahlsson, Dan Atar, Barbara Casadei, Manuel Castella, Hans-Christoph Diener, Hein Heidbuchel, Jeroen Hendriks, Gerhard Hindricks, Antonis S Manolis, Jonas Oldgren, Bogdan Alexandru Popescu, Ulrich Schotten, Bart Van Putte, Panagiotis Vardas
No abstract text is available yet for this article.
August 27, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27574717/association-of-clinical-factors-and-therapeutic-strategies-with-improvements-in-survival-following-non-st-elevation-myocardial-infarction-2003-2013
#4
Marlous Hall, Tatendashe B Dondo, Andrew T Yan, Shaun G Goodman, Héctor Bueno, Derek P Chew, David Brieger, Adam Timmis, Phillip D Batin, John E Deanfield, Harry Hemingway, Keith A A Fox, Christopher P Gale
IMPORTANCE: International studies report a decline in mortality following non-ST-elevation myocardial infarction (NSTEMI). Whether this is due to lower baseline risk or increased utilization of guideline-indicated treatments is unknown. OBJECTIVE: To determine whether changes in characteristics of patients with NSTEMI are associated with improvements in outcomes. DESIGN, SETTING, AND PARTICIPANTS: Data on patients with NSTEMI in 247 hospitals in England and Wales were obtained from the Myocardial Ischaemia National Audit Project between January 1, 2003, and June 30, 2013 (final follow-up, December 31, 2013)...
September 13, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27400984/drugs-that-may-cause-or-exacerbate-heart-failure-a-scientific-statement-from-the-american-heart-association
#5
Robert L Page, Cindy L O'Bryant, Davy Cheng, Tristan J Dow, Bonnie Ky, C Michael Stein, Anne P Spencer, Robin J Trupp, JoAnn Lindenfeld
Heart failure is a common, costly, and debilitating syndrome that is associated with a highly complex drug regimen, a large number of comorbidities, and a large and often disparate number of healthcare providers. All of these factors conspire to increase the risk of heart failure exacerbation by direct myocardial toxicity, drug-drug interactions, or both. This scientific statement is designed to serve as a comprehensive and accessible source of drugs that may cause or exacerbate heart failure to assist healthcare providers in improving the quality of care for these patients...
August 9, 2016: Circulation
https://www.readbyqxmd.com/read/27502078/acute-myocardial-infarction
#6
Grant W Reed, Jeffrey E Rossi, Christopher P Cannon
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins...
August 5, 2016: Lancet
https://www.readbyqxmd.com/read/27195814/intensive-vs-standard-blood-pressure-control-and-cardiovascular-disease-outcomes-in-adults-aged-%C3%A2-75-years-a-randomized-clinical-trial
#7
RANDOMIZED CONTROLLED TRIAL
Jeff D Williamson, Mark A Supiano, William B Applegate, Dan R Berlowitz, Ruth C Campbell, Glenn M Chertow, Larry J Fine, William E Haley, Amret T Hawfield, Joachim H Ix, Dalane W Kitzman, John B Kostis, Marie A Krousel-Wood, Lenore J Launer, Suzanne Oparil, Carlos J Rodriguez, Christianne L Roumie, Ronald I Shorr, Kaycee M Sink, Virginia G Wadley, Paul K Whelton, Jeffrey Whittle, Nancy F Woolard, Jackson T Wright, Nicholas M Pajewski
IMPORTANCE: The appropriate treatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncertain. OBJECTIVE: To evaluate the effects of intensive (<120 mm Hg) compared with standard (<140 mm Hg) SBP targets in persons aged 75 years or older with hypertension but without diabetes. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT)...
June 28, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27339497/the-diagnosis-and-evaluation-of-dilated-cardiomyopathy
#8
REVIEW
Alan G Japp, Ankur Gulati, Stuart A Cook, Martin R Cowie, Sanjay K Prasad
Dilated cardiomyopathy (DCM) is best understood as the final common response of myocardium to diverse genetic and environmental insults. A rigorous work-up can exclude alternative causes of left ventricular (LV) dilation and dysfunction, identify etiologies that may respond to specific treatments, and guide family screening. A significant proportion of DCM cases have an underlying genetic or inflammatory basis. Measurement of LV size and ejection fraction remain central to diagnosis, risk stratification, and treatment, but other aspects of cardiac remodeling inform prognosis and carry therapeutic implications...
June 28, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27323265/the-abc-stroke-risk-score-was-superior-to-the-cha2ds2-vasc-score-for-predicting-stroke-in-atrial-fibrillation
#9
Graeme J Hankey
No abstract text is available yet for this article.
June 21, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27208050/2016-acc-aha-hfsa-focused-update-on-new-pharmacological-therapy-for-heart-failure-an-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice
#10
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos Filippatos, Gregg C Fonarow, Michael M Givertz, Steven M Hollenberg, JoAnn Lindenfeld, Frederick A Masoudi, Patrick E McBride, Pamela N Peterson, Lynne Warner Stevenson, Cheryl Westlake
No abstract text is available yet for this article.
September 27, 2016: Circulation
https://www.readbyqxmd.com/read/27208049/updated-clinical-practice-guidelines-on-heart-failure-an-international-alignment
#11
Elliott M Antman, Jeroen Bax, Richard A Chazal, Mark A Creager, Gerasimos Filippatos, Jonathan L Halperin, Steven Houser, JoAnn Lindenfeld, Fausto J Pinto, Panos Vardas, Mary Norine Walsh, Kim A Williams, Jose L Zamorano
No abstract text is available yet for this article.
September 27, 2016: Circulation
https://www.readbyqxmd.com/read/27075872/after-topcat-what-to-do-now-in-heart-failure-with-preserved-ejection-fraction
#12
REVIEW
Akshay S Desai, Pardeep S Jhund
Although patients with heart failure and preserved ejection fraction (HF-PEF) represent nearly half of the population with chronic heart failure, few evidence-based medical therapies are available. The neutral overall results of the TOPCAT trial of spironolactone in HF-PEF leave clinicians who treat heart failure with an ongoing clinical dilemma. In this review, we outline an approach to the clinical management of the patient with HF-PEF synthesizing data from available clinical trials and expert consensus.
November 1, 2016: European Heart Journal
https://www.readbyqxmd.com/read/26768210/the-management-of-acute-coronary-syndromes-towards-optimal-treatment-of-stemi-and-non-stemi
#13
EDITORIAL
Thomas F Lüscher
No abstract text is available yet for this article.
January 14, 2016: European Heart Journal
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"